×
Achilles Therapeutics Income Taxes 2020-2024 | ACHL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Achilles Therapeutics income taxes from 2020 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.
View More
Achilles Therapeutics Income Taxes 2020-2024 | ACHL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Achilles Therapeutics income taxes from 2020 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$160.1B
Vertex Pharmaceuticals (VRTX)
$123.9B
Gilead Sciences (GILD)
$122.2B
Bristol Myers Squibb (BMY)
$116.5B
CSL (CSLLY)
$82.8B
Regeneron Pharmaceuticals (REGN)
$79.3B
GSK (GSK)
$75.4B
Argenex SE (ARGX)
$40B
Alnylam Pharmaceuticals (ALNY)
$35.9B
BioNTech SE (BNTX)
$28.8B
BeiGene (ONC)
$22.4B
Biogen (BIIB)
$20.7B
Illumina (ILMN)
$19.5B
Insmed (INSM)
$14.5B
Incyte (INCY)
$14.4B
Intra-Cellular Therapies (ITCI)
$13.5B
Moderna (MRNA)
$12.9B
Genmab (GMAB)
$12.8B
Genmab (GNMSF)
$12.7B
BioMarin Pharmaceutical (BMRN)
$12.3B
Bio-Techne Corp (TECH)
$11.9B
Vaxcyte (PCVX)
$11.1B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
Sarepta Therapeutics (SRPT)
$10.7B
Exact Sciences (EXAS)
$10B
Bio-Rad Laboratories (BIO.B)
$9.6B
Exelixis (EXEL)
$9.6B
QIAGEN (QGEN)
$9.4B
Repligen (RGEN)
$9.1B
Roivant Sciences (ROIV)
$7.9B